The Efficacy of Vitamin K2 n Human Osteoporosis, Blood-vessel Calcification and Sclerosis

Inclusion criteria

• Men and non-pregnant women who are at least 20 years and under 75 years of age; and
• Female subjects cannot be pregnant or breast feeding.
• Patients who are, in the opinion of the Investigator, able to comply with the requirements of the study; and
• Patients who have been adequately informed of the nature and risks of the study and who have given written informed consent prior to receiving study medication.

Exclusion criteria

• Women who are pregnant, as determined by a urine pregnancy test, or breast-feeding.
• Presence or history of congestive heart failure (NYHA class III/IV) within the prior 12 weeks.
• Recent myocardial infarction (within the prior 12 weeks).
• Unstable angina pectoris.
• Known or suspected renal insufficiency defined as creatinine>1.5mg/dl.
• Known or suspected hepatic insufficiency defined as abnormal liver function tests (GOT/GPT) >3x upper normal limit (i.e., 120 U/l).
• Known hypomotility syndrome: (such as hypothyroidism or scleroderma).
• Recent major trauma within the prior 12 weeks.
• Recent surgery requiring anesthesia including coronary artery bypass graft (within 12 weeks).
• Recent hospitalization (within 12 weeks)
• Uncontrolled hypertension (defined as a systolic blood pressure>180mmHg or a diastolic blood pressure >105mmHg).
• Uncontrolled hyperlipidemia (defined as total cholesterol>240mg/dL or triglyceride >200mg/dL).
• Uncontrolled diabetes (defined as HbA1c>7%).
• Cigarette smoker (>=1/day).
• Acute infection requiring current antibiotic therapy.
• Current use of anticoagulant medication (e.g., warfarin).
• Recent or abrupt change (within 1 month) in usual diet.
• Use of an investigational drug (within 30 days prior to enrollment).
• Known allergies to the component of study medication
• Patients have acute disease, and in the opinion of investigators, are not suitable to participate in this study.